Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion criteria:
Key Exclusion criteria:
Exclusion for Open-Label Extension (OLE):
Primary purpose
Allocation
Interventional model
Masking
975 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal